Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of JNJ-77474462 (Bermekimab) in Healthy Participants
NCT04544813Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1 trial of bermekimab in hidradenitis suppurativa (HS) and atopic dermatitis (AD) (10 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration Versus Time Curve and 2 more. Started Oct 2020; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04544813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544813.